Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 5/20 | 0.55 |
| ▸ | MPL | P40238 | 1/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29942640 | 0.81 | ALDH1A1 (0.59) | FEN1ALOX5APALDH1A1KDM4EIDO1 | |
| SCHEMBL4018259 | 0.79 | IDO1 (0.46) | MPLALDH1A1KDM4EIDO1NPC1 | |
| SCHEMBL29943290 | 0.76 | SMARCA2 (0.54) | FEN1ALDH1A1IDO1SMN1; SMN2MAPT | |
| SCHEMBL18038669 | 0.76 | SMARCA2 (0.54) | FEN1ALDH1A1IDO1SMN1; SMN2MAPT | |
| SCHEMBL4023321 | 0.76 | MEN1 (0.49) | MPLALDH1A1KDM4EIDO1NPC1 | |
| SCHEMBL16835822 | 0.76 | CNR2 (0.47) | FEN1ALOX5APALDH1A1KDM4EBACE1 | |
| SCHEMBL3169750 | 0.76 | IDO1 (0.43) | MPLALDH1A1KDM4EIDO1NPC1 | |
| SCHEMBL1916434 | 0.76 | HSP90AA1 (0.49) | FEN1ALDH1A1KDM4EBACE1IDO1 | |
| SCHEMBL13750512 | 0.76 | NPC1 (0.46) | MPLALDH1A1KDM4EIDO1NPC1 | |
| SCHEMBL20627193 | 0.76 | FEN1 (0.64) | FEN1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981964-B2 | Maleimide derivatives as modulators of wnt pathway | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-05-29 | — | — | US | disclosed |
| US-9981964-B2 | Maleimide derivatives as modulators of wnt pathway | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-05-29 | — | — | US | disclosed |
| US-9981964-B2 | Maleimide derivatives as modulators of wnt pathway | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-05-29 | — | — | US | disclosed |
| EP-3083622-B1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | AGENCY SCIENCE TECH & RES (SG) | 2018-03-21 | — | — | EP | disclosed |
| EP-3083622-B1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | AGENCY SCIENCE TECH & RES (SG) | 2018-03-21 | — | — | EP | disclosed |
| US-20160318926-A1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-11-03 | — | — | US | disclosed |
| US-20160318926-A1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-11-03 | — | — | US | disclosed |
| US-20160318926-A1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-11-03 | — | — | US | disclosed |
| EP-3083622-A1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | Agency For Science, Technology And Research (SG) | 2016-10-26 | — | — | EP | disclosed |
| CN-106061974-A | Maleimide derivatives as modulators of WNT pathway | 新加坡科技研究局 | 2016-10-26 | — | — | CN | disclosed |
| US-8871767-B2 | 2-arylimidazo[1,2-B]pyridazine, 2-phenylimidazo[1,2-A]pyridine, and 2-phenylimidazo[1,2-A]pyrazine derivatives | HENGRUI (USA) LTD. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871767-B2 | 2-arylimidazo[1,2-B]pyridazine, 2-phenylimidazo[1,2-A]pyridine, and 2-phenylimidazo[1,2-A]pyrazine derivatives | HENGRUI (USA) LTD. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871767-B2 | 2-arylimidazo[1,2-B]pyridazine, 2-phenylimidazo[1,2-A]pyridine, and 2-phenylimidazo[1,2-A]pyrazine derivatives | HENGRUI (USA) LTD. (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2635578-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | Hengrui (USA) Ltd. (US) | 2013-09-11 | — | — | EP | disclosed |
| CN-103261198-A | 2-arylimidazo[1,2-]pyridazine, 2-phenylimidazo[1,2-a]pyridine, and 2-phenylimidazo[1,2-a]pyrazine derivatives | JIANGSU HENGRUI MEDICINE CO | 2013-08-21 | — | — | CN | disclosed |
| US-20120178751-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | HENGRUI (USA), LTD. | 2012-07-12 | — | — | US | disclosed |
| US-20120178751-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | HENGRUI (USA), LTD. | 2012-07-12 | — | — | US | disclosed |
| US-20120178751-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | HENGRUI (USA), LTD. | 2012-07-12 | — | — | US | disclosed |
| WO-2012088411-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | PAMLICO PHARMACEUTICAL INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012088411-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | PAMLICO PHARMACEUTICAL INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318926-A1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | WNT1, WNT3, CTNNB1 | FEN1 2876/4885MPL 4737/4885ALOX5AP 4151/4885 |
| US-20120178751-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | PRXL2A, CDK2, CCNA2 | FEN1 2810/4885MPL 744/4885ALOX5AP 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.